Clarivate Plc (NYSE:CLVT) announced Tuesday it will integrate its Cortellis Regulatory Intelligence (CRI) data with Claude, the AI assistant developed by Anthropic, to expand access to trusted regulatory insights within enterprise AI workflows.
The integration uses the open Model Context Protocol (MCP) to connect Clarivate’s proprietary regulatory intelligence with Claude’s natural language reasoning capabilities. As a result, biopharma, biotech, medtech, and clinical research organizations can access authoritative, referenced regulatory information directly within the AI tools they already use.
The CRI MCP will allow regulatory affairs, pharmacovigilance, and life sciences teams to obtain accurate answers grounded in industry-validated sources. It is available to customers using both Clarivate CRI and Claude.
Henry Levy, president of Life Sciences & Healthcare at Clarivate, said the integration advances the company’s strategy to extend its intelligence into enterprise AI ecosystems where critical decisions are made.
The move also enables organizations to build AI agents that combine CRI insights with internal data and approved external sources to monitor regulatory changes and support decision-making.
Stock Performance Analysis
Over the past 12 months, Clarivate’s stock has declined 39.72%. Currently, the stock is trading at $2.63, which is slightly below its 50-day SMA of $2.66 and significantly below the 100-day SMA of $3.10. This positioning suggests a bearish long-term trend, despite recent gains in the premarket.
The technical indicators present a mixed outlook. The RSI stands at 57.72, suggesting a neutral market sentiment, while the MACD indicates a bullish signal, with the MACD line at 17 cents above the signal line. This divergence between the RSI and MACD may suggest potential upcoming volatility or a shift in market dynamics.
Earnings Expectations
Clarivate is estimated to report its next earnings on April 28, 2026.
- EPS Estimate: 13 cents (Down from 14 cents YoY)
- Revenue Estimate: $569.31 million (Down from $593.70 million YoY)
Analyst Consensus & Recent Actions: The stock carries an Underweight Rating with an average price target of $4.81. Recent analyst moves include:
- Citigroup: Neutral (Lowers Target to $2.80) (Mar. 4)
- Barclays: Underweight (Lowers Target to $2.40) (Feb. 25)
- RBC Capital: Sector Perform (Lowers Target to $3.00) (Feb. 25)
CLVT Price Action: Clarivate shares were up 0.77% at $2.63 in after-hours trading on Monday, according to Benzinga Pro data.
Image via Shutterstock
This article Clarivate Brings Trusted Regulatory Intelligence To Claude's AI Ecosystem originally appeared on Benzinga.com
.
